As a member of the pharmacology group, we seek a scientifically curious and motivated individual with an ability to work in a fast-paced environment. The potential Research Associate will develop and execute the ligand binding assay based bioanalytical method development to support pharmacokinetics (PK) sample analysis. In addition, the candidate will have opportunity to analyze high volume of data and to develop in vitro assays for compound characterization using ELISA, Octet, and cell-based assays. This position is hands-on and requires the effective experiment execution, communication, and documentation of results that enable the advancement of novel research molecules toward development candidates. Strong candidates will be hard working, efficient, collaborative, and passionate about drug discovery and development. Experience in ligand binding assay development and routine sample analysis is desired. This position will report directly to the Scientist of in vivo Pharmacology.
ESSENTIAL FUNCTIONS AND RESPONSIBILITIES
- Identify, develop and execute ligand binding assays and other in vitro assays to support both in vivo and in vitro pharmacology studies.
- Proven track record of ligand binding assay development and participation of routine preclinical and/or clinical sample analysis. Execute assays from assay development, qualification (if required), sample analysis, data analysis, and report by following the instruction or established procedure.
- Analyze and present experimental data using Prism, Excel, MS Office or similar software.
- Produce detailed documentation of experiments within a lab notebook and electronically.
- Ability to schedule and prioritize workload effectively within a multi-task environment.
These may include, but are not limited to:
EDUCATION, EXPERIENCE, KNOWLEDGE, SKILLS AND ABILITIES
- A bachelor’s degree with a minimum of 2 years of relevant experience or a master’s degree with a minimum of 1 year of relevant industry experience.
- Experience in ligand binding assay development, qualification/validation and sample analysis.
- Competence in data analysis tools (Excel, GraphPad). Candidates with experience in data management, coding and programming in Excel or other data management software would be a plus.
- Hands-on expertise with ELISA and MSD is highly desirable.
- Experience with cell-based assays is a plus.
- Experience with immunogenicity/ADA sample analysis is a plus.
- Ability to perform routine testing and to follow SOPs in a highly accurate and reproducible manner.
- Strong analytical and critical thinking skills with the ability to work in a fast-paced and collaborative environment.
- Excellent written and oral communication skills.
Skills Required
- Bachelor's degree with at least 2 years of relevant experience
- Master's degree with at least 1 year of relevant industry experience
- Experience developing, qualifying or validating, and analyzing ligand-binding assays
- Experience with routine preclinical or clinical sample analysis
- Competence with Excel and GraphPad data analysis tools
- Hands-on expertise with ELISA and MSD
- Experience with cell-based assays
- Experience with immunogenicity or ADA sample analysis
- Ability to perform routine testing and follow SOPs accurately and reproducibly
- Strong analytical and critical thinking skills
- Excellent written and oral communication skills
What We Do
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
